Department of Internal Medicine, University of Ioannina, Ioannina, Greece.
Clin Exp Rheumatol. 2013 Jan-Feb;31(1):47-52. Epub 2012 Sep 25.
This paper aims to describe the clinical manifestations, laboratory abnormalities and treatment of adult-onset Still's disease (AOSD) in Greek patients.
This is a retrospective observational study. Forty-four patients, diagnosed with AOSD, followed since 1985 up to June 2011, were included. The disease course and treatment were recorded and compared to previously published studies.
Twenty-one males and 23 females were identified. Mean age at diagnosis was 38.3 years. The most common clinical manifestations were fever (100%), arthralgias (97.7%), arthritis (93.2%), salmon-coloured rash (84%), myalgias (50%) and sore throat (38.6%). Characteristic laboratory abnormalities were leucocytosis with neutrophilia (81.8%), elevated C-reactive protein (100%) and erythrocyte sedimentation rate (100%). Elevated liver enzymes and hyperferritinaemia were found in 50% and in 59% of the patients respectively. Very high ferritin serum levels (>5000 μg/l) were found in 22.7%. Rheumatoid factor and antinuclear antibodies were negative in all patients. Thirty patients (68.2%) received non-steroidal anti-inflammatory drugs or aspirin with or without corticosteroids. Response to corticosteroids was common (58.9%). When this treatment was ineffective, a disease-modifying anti-rheumatic drug (DMARD), usually methotrexate, was added with a response rate of 63.6%. Anakinra was used in cases resistant to conventional immunosuppressive treatment. Ten out of 44 patients (22.7%) were treated with anakinra and response was achieved in all of them.
Our results regarding clinical manifestations and laboratory abnormalities were similar to those of previous reports. High ferritin serum levels were reported in all studies of AOSD and are considered as diagnostically valuable. When treatment with corticosteroids and DMARDS had failed, biologic agents such as anakinra were successfully applied.
本文旨在描述希腊成人斯蒂尔病(AOSD)患者的临床表现、实验室异常和治疗方法。
这是一项回顾性观察性研究。共纳入自 1985 年至 2011 年 6 月期间诊断为 AOSD 的 44 例患者。记录了疾病过程和治疗方法,并与之前发表的研究进行了比较。
共纳入 21 名男性和 23 名女性患者,诊断时的平均年龄为 38.3 岁。最常见的临床表现为发热(100%)、关节痛(97.7%)、关节炎(93.2%)、鲑鱼色皮疹(84%)、肌痛(50%)和咽痛(38.6%)。特征性实验室异常包括白细胞增多伴中性粒细胞增多(81.8%)、C 反应蛋白升高(100%)和红细胞沉降率升高(100%)。50%的患者肝功能酶升高,59%的患者铁蛋白升高。22.7%的患者血清铁蛋白水平非常高(>5000μg/l)。所有患者的类风湿因子和抗核抗体均为阴性。30 例(68.2%)患者接受非甾体抗炎药或阿司匹林联合或不联合皮质类固醇治疗。皮质类固醇治疗有效率为 58.9%。当这种治疗无效时,添加一种疾病修饰抗风湿药物(DMARD),通常是甲氨蝶呤,有效率为 63.6%。对于常规免疫抑制治疗无效的患者,使用阿那白滞素。44 例患者中有 10 例(22.7%)接受了阿那白滞素治疗,所有患者均有效。
我们的研究结果在临床表现和实验室异常方面与之前的报告相似。所有 AOSD 研究均报告了高血清铁蛋白水平,这被认为具有诊断价值。当皮质类固醇和 DMARD 治疗失败时,成功应用了生物制剂如阿那白滞素。